# Jefferies
# Global Healthcare Conference

November 18, 2026

© 2026 Haemonetics Corporation

HAEMONETICS®

# Important Information

## Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "forecasts," "foresees," "potential" and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for operations of Haemonetics Corporation ("Haemonetics" or the "Company"), including plans or objectives related to the Company's strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company's market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company's share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results can be found in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q with the U.S. Securities Exchange Commission (the "SEC") under the headings "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" and in the Company's other periodic filings with the SEC. The Company does not undertake to update these forward-looking statements.


## Non-GAAP Financial Measures


This presentation contains non-GAAP financial measures as defined under applicable SEC rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with U.S. GAAP. We strongly encourage investors to review the Company's financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. To the extent available without unreasonable effort, we have provided reconciliations of these non-GAAP measures to their most comparable GAAP measure in the appendix to this presentation, which is available on our website at www.haemonetics.com. With the exception of fiscal 2027 total Company revenue guidance, the Company does not provide a reconciliation of forward-looking non-GAAP measures because certain significant information necessary for such reconciliations are unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts.


© 2026 Haemonetics Corporation

# Haemonetics at a Glance

## FY'26 REVENUE




**HAE**
NYSE ticker

**~$5.6B**
Market Cap[1]

**3000+**
employees

1) Market capitalization as of November 13, 2026.


© 2026 Haemonetics Corporation

HAEMONETICS®

# Strategy Focused on Market Leadership and Profitable Growth

**Compete in winning segments and geographies**

**Achieve leading positions**

**Deliver superior operating performance**

## GOALS

### GROWTH



Revenue



Profitability



Cash Flow

### DIVERSIFICATION

- Business Segments
- Customers
- Geographies
- Business Models

### SUSTAINABILITY

- Economic
- People
- Societal
- Environmental


© 2026 Haemonetics Corporation

HAEMONETICS®

# A Durable, High-Return Model Built to Compound Value

## Recurring Revenue

**94%**

Disposables and software embedded in customer workflows[1]

## Focused Growth Strategy

- Portfolio concentrated in attractive, high-growth markets
- Multiple growth vectors support sustained above-market growth
- Disciplined capital allocation targets high-return opportunities

## Proven Execution

| | |
|---|---|
| **10%** | Organic Revenue CAGR[2] |
| **18%** | Adjusted EPS CAGR[2] |
| **111%** | FCF conversion Ratio (TTM)[3] |

1) Recurring revenue includes single-use disposables and software expressed as a percentage of total Company revenue. 2) Compounded average growth rates for FY'22 – FY'26. 3) Free cash flow to adjusted net income conversion ratio for the twelve trailing months as of Q2 FY'27.


© 2026 Haemonetics Corporation
HAEMONETICS®

# Three Core Products With Leading Positions Driving Nearly All Revenue Growth

## Plasma

**FY'26 Revenue**







**#1**

in plasma collections with **NexSys PCS®**

## Blood Management Technologies

**FY'26 Revenue**







**#1**

in viscoelastic testing with **TEG®6s** (Hemostasis Management)

## Interventional Technologies

**FY'26 Revenue**






**#1**

in electrophysiology with **VASCADE MVP®** (Vascular Closure)

Note: Availability of products may vary from one country or region to another as a result of specific local regulatory approval or clearance requirements.



© 2026 Haemonetics Corporation
HAEMONETICS®

# Driving Sustained Market Leadership with Industry-Defining Plasma Innovation

## PLASMA MARKET

**~$1B SAM[1]**


growing MSD-HSD




## The only provider of fully integrated plasma collection solutions focused on reducing Cost Per Liter (CPL)

### DELIVERING UNRIVALED PLASMA CENTER CAPABILITIES

1. Yield
2. Productivity
3. Safety
4. Donor Experience




## DRIVERS OF REVENUE GROWTH

| Growth in plasma collections | Global market share expansion | Innovation focused on top customer KPI's |
|---|---|---|

1) Serviceable Addressable Market (SAM) is calculated as total plasma collections (excluding China) in fiscal year 2026 multiplied by the average selling price of Haemonetics' total product offerings in each geography. [US plasma collections data is from PPTA, Europe & ROW collections data is from the "Global Blood & Plasma Collections and Use 2023/2024" report by MRB, Sep. 2025.].


Note: Availability of products may vary from one country or region to another as a result of specific local regulatory approval or clearance requirements.



© 2026 Haemonetics Corporation
HAEMONETICS®

# Building Momentum and Making TEG® 6s the Standard for Viscoelastic Testing

## VISCOELASTIC TESTING (VET) MARKET

**~$420M SAM[1]**
growing MSD




## TEG® 6s is the only integrated VET system, and the only system offering PlateletMapping® functionality


TEG® 6s


TEG Manager® software

**Real-time**, **actionable insight** into coagulation status designed to: enable clinicians to make **rapid, targeted treatment decisions, help improve patient outcomes** and **help reduce costs** and **risks** of unnecessary transfusions.

## DRIVERS OF REVENUE GROWTH

Penetration in the top 700 accounts in the US; international expansion

Pipeline of innovation
- Clinical segments
- Product portfolio


1) Serviceable Addressable Market reflects existing commercial geographies and indications. Data sources include iData, DRG/Clarivate, MedTech Insight, and internal Company estimates. Includes the Top 7 geographies multiplied by average test utilization and average selling price in each geography.
Note: Availability of products may vary from one country or region to another as a result of specific local regulatory approval or clearance requirements.


© 2026 Haemonetics Corporation
HAEMONETICS®

# Expanding Market and Growth Momentum in Electrophysiology with Vascular Closure

## ELECTROPHYSIOLOGY MARKET

**~$600M SAM[1]**
growing MSD - HSD




## Robust clinical evidence[3] supporting continued adoption and market share leadership in EP

Simple-to-use resorbable collagen plug that expands to fill the tissue track

**64%** reduction in median time to ambulation

**63%** Improvement in patient satisfaction[4]

**58%** Reduction in opioid use




## DRIVERS OF REVENUE GROWTH

| | | |
|---|---|---|
| Penetration into the Top 600 accounts in the US; international expansion | Increase in the utilization of existing accounts | Pipeline of innovation<br>• Clinical segments<br>• Product portfolio |


1) Serviceable Addressable Market reflects existing commercial geographies and is calculated as total procedure volumes multiplied by average selling price by region. Procedure data sourced from Clarivate and MRB. 2) Afib – Atrial Fibrillation ablation, LAAC - Left Atrial Appendage Closure, VT – Ventricular Tachycardia ablation, SVT – Supraventricular Tachycardia, FL – Atrial Flutter. 3) As demonstrated in the AMBULATE pivotal trial, compared to manual compression. 4) Patient satisfaction data on a scale of 0-10, with 0 being the worst and 10 being the best. Note: Availability of products may vary from one country or region to another as a result of specific local regulatory approval or clearance requirements.


© 2026 Haemonetics Corporation
HAEMONETICS®

# A Track Record of Improving Profitability and Free Cash Flow


## Adjusted Operating Margin %

**+660**bps





## Adjusted EPS

**18%** CAGR




## Free Cash Flow

**2.7X**





© 2026 Haemonetics Corporation
HAEMONETICS®

# Q2 FY'27 Year-to-Date Results and Fiscal 2027 Guidance

| | YTD Q2 FY'27 Actual | FY'27 Guidance (as issued November 5, 2026) |
|---|---|---|
| **Reported revenue growth** | **7.5%**<br>$697M revenue | **8–11%** |
| **Organic revenue growth[2]** | **8.0%**<br>Ex currency and strategic exits[1] | **6–9%** |
| **Apheresis**<br>Organic growth | **9.8%**<br>$396M revenue; +9.0% reported | **High-single-digit**<br>growth |
| **MedSurg**<br>Organic growth | **5.7%**<br>$301M revenue; +5.6% reported | **Mid-single-digit**<br>growth |
| **Adjusted operating margin** | **24.9%**<br>Down 50 bps YoY | **0–50 bps**<br>expansion YoY |
| **Adjusted diluted EPS** | **$2.49**<br>+5.5% YoY | **Growth comparable**<br>to reported revenue growth |
| **Free cash flow conversion[3]** | **$143M FCF**<br>124% of adjusted net income | **>80%[4]** |


1) Strategic exits include the exit of certain liquid solution products. 2) Organic growth guidance includes nominal historical pre-acquisition revenue of Vivasure for comparability. 3) Free cash flow conversion equals free cash flow divided by adjusted net income. YTD organic revenue growth and adjusted measures are non-GAAP; see appendix for reconciliations. 4) Inclusive of capital investments and higher working capital needed to convert CSL plasma centers in the US.


© 2026 Haemonetics Corporation
HAEMONETICS®

# Value-Enhancing Capital Allocation

A relentless focus on **shareholder value creation**

Consistent **strong cash generation** creates **optionality for capital deployment**





© 2026 Haemonetics Corporation
HAEMONETICS®

# What Our Momentum Means for Shareholders



**Sustained above-market growth runway**



**Greater earnings power**



**More flexibility to deploy capital**


© 2026 Haemonetics Corporation
HAEMONETICS®

# Appendices


© 2026 Haemonetics Corporation

# Appendix A: Reconciliation of GAAP Revenue to Organic Revenue Compounded Annual Growth Rate (CAGR)

| (Revenue $ in millions) | FY 2026 | FY 2022 | |
|---|---|---|---|
| | Actual | Actual | CAGR |
| **Reported Revenue** | **$1,334.0** | **$993.2** | **7.7%** |
| Acquisitions and Divestitures Impact | ($47.7) | ($76.4) | |
| Currency Impact | ($16.9) | ($45.4) | |
| **Organic Revenue[1]** | **$1,269.4** | **$871.4** | **9.9%** |

1) Reflects revenue related to the Attune Medical, OpSens Inc. acquisitions and the divestiture of the Whole Blood business.


© 2026 Haemonetics Corporation

# Appendix A: Reconciliation of Reported to Organic Revenue Growth Q2 YTD Fiscal 2027

| (% growth vs. prior year period) | Reported growth | Currency impact | Strategic exits[1] | Organic growth[2] |
|---|---|---|---|---|
| Plasma | 11.7% | (0.3)% | (0.9)% | 12.9% |
| Other[3] | (1.1)% | 0.1% | – | (1.2)% |
| **Apheresis** | **9.0%** | **(0.1)%** | **(0.7)%** | **9.8%** |
| Interventional Technologies[4] | 2.5% | (0.5)% | – | 3.0% |
| Blood Management Technologies[5] | 7.7% | 0.2% | – | 7.5% |
| **MedSurg** | **5.6%** | **(0.1)%** | **–** | **5.7%** |
| **Total net revenues** | **7.5%** | **(0.1)%** | **(0.4)%** | **8.0%** |

1) Includes the impact of the exit of certain liquid solution products. 2) Includes nominal historical pre-acquisition revenue of Vivasure. 3) Other includes blood collection and processing devices and disposables. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit. 5) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.


© 2026 Haemonetics Corporation

# Appendix A: Reconciliation of Reported to Organic FY'27 Revenue Growth Guidance

| Total Company | Fiscal 2027 Guidance (as issued November 5, 2026) |
|---|---|
| **Reported Revenue** | **8 - 11%** |
| 53rd week impact | (~2%) |
| Strategic exits[1] | ~1% |
| Currency impact | 0 - 1% |
| **Organic Revenue[2]** | **6 - 9%** |
| Adjusted operating margin | 0 – 50 bps expansion YoY |
| Adjusted earnings per diluted share | Comparable to reported revenue growth |
| Free cash flow conversion[3] | >80% |

1) Includes the impact of the exit of certain liquid solution products. 2) Guidance includes high-single-digit growth in Apheresis and mid-single digit growth in MedSurg. Organic growth guidance also includes nominal historical pre-acquisition revenue of Vivasure to provide a comparable view of period-over-period performance. 3) Free cash flow conversion is calculated as free cash flow divided by adjusted net income. Source: Q2 FY'27 earnings release, November 5, 2026.


© 2026 Haemonetics Corporation

# Appendix B: Reconciliation of GAAP to Non-GAAP Q2 YTD Fiscal 2027 Financial Results

| ($ millions) | Gross profit | Operating expenses | Operating income (loss) | Interest and other expense | Provision (benefit) for income taxes | Net income (loss) | Earnings (loss) per diluted share |
|---|---|---|---|---|---|---|---|
| Reported | $423.7 | $291.1 | $132.6 | ($22.1) | $31.1 | $79.3 | $1.72 |
| Amortization of acquired intangible assets | – | ($20.6) | $20.6 | – | $4.4 | $16.2 | $0.35 |
| Integration and transaction costs | $2.2 | ($3.1) | $5.3 | ($0.0) | ($0.3) | $5.6 | $0.12 |
| Restructuring costs | $0.6 | ($1.5) | $2.1 | – | $0.5 | $1.6 | $0.03 |
| Restructuring related costs | $0.0 | $0.1 | ($0.0) | – | – | ($0.0) | – |
| Digital transformation costs | – | ($11.6) | $11.6 | – | $2.9 | $8.7 | $0.19 |
| Litigation-related charges | – | ($0.5) | $0.5 | – | – | $0.5 | $0.01 |
| Remeasurement of contingent consideration | – | ($0.7) | $0.7 | – | $0.2 | $0.5 | $0.01 |
| Equity method losses | – | – | – | $2.4 | $0.6 | $1.8 | $0.04 |
| Discrete tax items | – | – | – | – | ($0.7) | $0.7 | $0.02 |
| Adjusted | $426.5 | $253.2 | $173.3 | ($19.8) | $38.7 | $114.9 | $2.49 |
| Adjusted, as a percentage of net revenues | 61.2% | 36.3% | 24.9% | | | 16.5% | |


© 2026 Haemonetics Corporation

# Appendix B: Reconciliation of GAAP to Non-GAAP Q2 YTD Fiscal 2026 Financial Results

| ($ millions) | Gross profit | Operating expenses | Operating income (loss) | Interest and other expense | Provision (benefit) for income taxes | Net income (loss) | Earnings (loss) per diluted share |
|---|---|---|---|---|---|---|---|
| Reported | $387.0 | $274.6 | $112.4 | ($15.9) | $23.7 | $72.7 | $1.51 |
| Amortization of acquired intangible assets | – | ($22.6) | $22.6 | – | $5.7 | $16.8 | $0.36 |
| Amortization of fair value inventory step-up | $4.5 | – | $4.5 | – | $1.1 | $3.4 | $0.07 |
| Integration and transaction costs | $2.4 | ($1.8) | $4.2 | $2.0 | $1.6 | $4.6 | $0.10 |
| Restructuring costs | ($0.5) | ($2.0) | $1.5 | – | $0.4 | $1.1 | $0.02 |
| Restructuring related costs | $0.0 | ($0.1) | $0.1 | – | $0.0 | $0.1 | – |
| Digital transformation costs | – | ($10.4) | $10.4 | – | $2.6 | $7.8 | $0.16 |
| Litigation-related charges | – | ($0.8) | $0.8 | – | $0.2 | $0.6 | $0.01 |
| Impairment of intangible assets | – | ($8.6) | $8.6 | – | $2.1 | $6.4 | $0.13 |
| Remeasurement of contingent consideration | – | $0.2 | ($0.2) | – | ($0.1) | ($0.1) | – |
| Adjusted | $393.3 | $228.5 | $164.8 | ($13.9) | $37.4 | $113.5 | $2.36 |
| Adjusted, as a percentage of net revenues | 60.6% | 35.2% | 25.4% | | | 17.5% | |


© 2026 Haemonetics Corporation

# Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2026 Financial Results

| ($ millions) | Gross profit | Operating expenses | Operating income (loss) | Interest and other expense | Provision (benefit) for income taxes | Net income (loss) | Earnings (loss) per diluted share |
|---|---|---|---|---|---|---|---|
| Reported | $787.6 | $630.9 | $156.7 | ($28.7) | $30.7 | $97.3 | $2.05 |
| Amortization of acquired intangible assets | – | ($44.0) | $44.0 | – | $10.8 | $33.2 | $0.70 |
| Amortization of fair value inventory step-up | $5.8 | – | $5.8 | – | $1.4 | $4.4 | $0.09 |
| Acquisition, integration and transaction costs | $3.7 | ($10.5) | $14.2 | $2.3 | $4.0 | $12.5 | $0.26 |
| Restructuring costs | ($0.5) | ($3.6) | $3.1 | – | $0.8 | $2.3 | $0.05 |
| Restructuring related costs | – | ($0.1) | $0.1 | – | $0.0 | $0.1 | – |
| Digital transformation costs | – | ($21.5) | $21.5 | – | $5.2 | $16.3 | $0.34 |
| Write downs of certain assets | – | ($1.0) | $1.0 | – | $0.3 | $0.7 | $0.02 |
| Litigation-related charges | – | – | – | – | – | $0.0 | – |
| Impairment of intangible assets | – | ($86.5) | $86.5 | – | $21.3 | $65.3 | $1.38 |
| Remeasurement of contingent consideration | – | $1.9 | ($1.9) | – | ($0.9) | ($1.0) | ($0.02) |
| Provision for pre-acquisition inventory and inventory purchase commitments | $7.4 | – | $7.4 | – | $1.9 | $5.5 | $0.12 |
| Discrete tax items | – | – | – | – | $1.9 | ($1.9) | ($0.03) |
| Adjusted | $804.0 | $465.5 | $338.5 | ($26.4) | $77.4 | $234.7 | $4.96 |
| Adjusted, as a percentage of net revenues | 60.3% | 34.9% | 25.4% | | | 17.6% | |


© 2026 Haemonetics Corporation

# Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2025 Financial Results

| ($ millions) | Gross profit | Operating expenses | Operating income (loss) | Interest and other expense | Provision (benefit) for income taxes | Net income (loss) | Earnings per diluted share |
|---|---|---|---|---|---|---|---|
| Reported | $749.0 | $527.1 | $221.8 | ($9.7) | $44.4 | $167.7 | $3.31 |
| Amortization of acquired intangible assets | – | ($48.3) | $48.3 | – | $12.0 | $36.3 | $0.72 |
| Amortization of fair value inventory step up | $15.0 | – | $15.0 | – | $3.6 | $11.3 | $0.22 |
| Acquisition, integration and divestiture related costs | $3.2 | ($19.7) | $22.9 | ($2.5) | $2.4 | $18.0 | $0.35 |
| Restructuring costs | $11.3 | ($2.6) | $13.9 | – | $3.5 | $10.4 | $0.21 |
| Restructuring related costs | $3.3 | ($3.9) | $7.2 | – | $1.7 | $5.6 | $0.11 |
| Digital transformation costs | – | ($20.3) | $20.3 | – | $4.8 | $15.5 | $0.30 |
| PCS2 related charges | – | ($4.0) | $4.0 | – | $1.0 | $3.0 | $0.06 |
| MDR and IVDR costs | $0.0 | ($4.8) | $4.8 | – | $1.1 | $3.7 | $0.07 |
| Litigation-related charges | – | ($2.9) | $2.9 | – | $0.7 | $2.2 | $0.04 |
| Gain on repurchase of convertible notes, net | – | – | – | ($12.6) | ($3.1) | ($9.5) | ($0.19) |
| Gain on sale of property, plant and equipment | – | $14.1 | ($14.1) | – | ($3.4) | ($10.7) | ($0.21) |
| Impairment of intangible assets | – | ($2.4) | $2.4 | – | $0.6 | $1.8 | $0.04 |
| Remeasurement of contingent consideration | – | $23.0 | ($23.0) | – | ($0.1) | ($23.0) | ($0.45) |
| Discrete tax items | – | – | – | – | $0.7 | ($0.7) | ($0.01) |
| Adjusted | $781.8 | $455.5 | $326.3 | ($24.8) | $70.0 | $231.5 | $4.57 |
| Adjusted, as a percentage of net revenues | 57.4% | 33.5% | 24.0% | | | 17.0% | |


© 2026 Haemonetics Corporation

# Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2024 Financial Results

| ($ millions) | Gross profit | Operating expenses | Operating income (loss) | Interest and other expense | Provision (benefit) for income taxes | Net income (loss) | Earnings per diluted share |
|---|---|---|---|---|---|---|---|
| Reported | $691.5 | $526.7 | $164.9 | ($13.0) | $34.3 | $117.6 | $2.29 |
| Amortization of acquired intangible assets | – | ($32.0) | $32.0 | – | $8.2 | $23.8 | $0.46 |
| Amortization of fair value inventory step up | $3.3 | – | $3.3 | – | $0.9 | $2.5 | $0.05 |
| Acquisition, integration and divestiture related costs | $0.0 | ($11.2) | $11.2 | – | $1.3 | $9.9 | $0.19 |
| Restructuring costs | $11.3 | ($2.8) | $14.1 | – | $3.2 | $10.9 | $0.21 |
| Restructuring related costs | $5.7 | ($3.8) | $9.5 | – | $2.4 | $7.1 | $0.14 |
| Digital transformation costs | – | ($15.7) | $15.7 | – | $3.9 | $11.8 | $0.23 |
| PCS2 related charges | $0.3 | ($4.8) | $5.1 | – | $1.3 | $3.8 | $0.07 |
| MDR and IVDR costs | – | ($5.6) | $5.6 | – | $1.3 | $4.3 | $0.08 |
| Litigation-related charges | – | ($6.7) | $6.7 | – | $1.7 | $5.0 | $0.10 |
| Impairment of intangible assets | – | ($10.4) | $10.4 | – | $3.4 | $7.0 | $0.14 |
| Gain on divestiture | – | $2.0 | ($2.0) | – | ($0.5) | ($1.5) | ($0.03) |
| Discrete tax items | – | – | – | – | ($1.5) | $1.5 | $0.03 |
| Adjusted | $712.3 | $435.7 | $276.5 | ($13.0) | $59.9 | $203.6 | $3.96 |
| Adjusted, as a percentage of net revenues | 54.4% | 33.3% | 21.1% | | | 15.6% | |


© 2026 Haemonetics Corporation

# Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2023 Financial Results

| ($ millions) | Gross profit | Operating expenses | Operating income (loss) | Interest and other expense | Provision (benefit) for income taxes | Net income (loss) | Earnings per diluted share |
|---|---|---|---|---|---|---|---|
| Reported | $615.1 | $459.1 | $156.0 | ($14.6) | $26.0 | $115.4 | $2.24 |
| Amortization of acquired intangible assets | – | ($32.6) | $32.6 | – | $10.0 | $22.7 | $0.44 |
| Integration and transaction costs | – | $0.4 | ($0.4) | – | ($0.1) | ($0.3) | ($0.01) |
| Restructuring costs | ($0.2) | ($0.9) | $0.7 | – | $0.2 | $0.5 | $0.01 |
| Restructuring related costs | $8.0 | ($2.9) | $10.9 | – | $3.1 | $7.8 | $0.16 |
| Digital transformation costs | – | ($4.5) | $4.5 | – | $1.6 | $3.0 | $0.06 |
| Write downs of certain in-process intangible assets and PCS2 related charges | ($1.0) | ($0.4) | ($0.6) | – | ($0.2) | ($0.4) | ($0.01) |
| MDR and IVDR costs | $0.1 | ($9.8) | $9.9 | – | $2.8 | $7.1 | $0.14 |
| Litigation-related charges | – | ($5.2) | $5.2 | – | $1.8 | $3.5 | $0.07 |
| Gain on sale of assets | – | $0.4 | ($0.4) | – | ($0.1) | ($0.3) | ($0.01) |
| Discrete tax adjustments | – | – | – | – | $3.2 | ($3.2) | ($0.06) |
| Adjusted | $622.0 | $403.6 | $218.4 | ($14.6) | $48.1 | $155.7 | $3.03 |
| Adjusted, as a percentage of net revenues | 53.2% | 34.5% | 18.7% | | | 13.3% | |


© 2026 Haemonetics Corporation

# Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2022 Financial Results

| ($ millions) | Gross profit | Operating expenses | Operating income (loss) | Interest and other expense | Provision (benefit) for income taxes | Net income (loss) | Earnings per diluted share |
|---|---|---|---|---|---|---|---|
| Reported | $505.5 | $424.8 | $80.8 | ($17.1) | $20.3 | $43.4 | $0.84 |
| Amortization of acquired intangible assets | – | ($47.4) | $47.4 | – | $9.7 | $37.7 | $0.73 |
| Integration and transaction costs | $5.3 | ($16.3) | $21.6 | – | $4.5 | $17.1 | $0.33 |
| Restructuring costs | $2.2 | ($2.0) | $4.2 | – | $0.5 | $3.7 | $0.07 |
| Restructuring related costs | $17.8 | ($6.8) | $24.6 | – | $5.2 | $19.4 | $0.38 |
| Impairment of assets and PCS2 related charges | $4.9 | ($0.9) | $5.7 | – | $1.2 | $4.5 | $0.09 |
| MDR and IVDR costs | – | ($11.0) | $11.0 | – | $2.3 | $8.7 | $0.17 |
| Litigation-related charges | – | ($1.4) | $1.4 | – | $0.3 | $1.1 | $0.02 |
| Gain on divestiture | – | $9.6 | ($9.6) | – | ($2.0) | ($7.6) | ($0.15) |
| Discrete tax adjustments | – | – | – | – | ($4.6) | $4.6 | $0.10 |
| Adjusted | $535.7 | $348.6 | $187.1 | ($17.1) | $37.4 | $132.6 | $2.58 |
| Adjusted, as a percentage of net revenues | 53.9% | 35.1% | 18.8% | | | 13.3% | |


© 2026 Haemonetics Corporation

# Appendix C: Reconciliation of Cash Flows

| ($ millions) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Free Cash Flow Reconciliation | | | | | |
| Cash provided by operating activities | $293.2 | $181.7 | $181.8 | $273.1 | $172.3 |
| Capital expenditures | ($32.8) | ($39.3) | ($38.1) | ($29.1) | ($44.7) |
| Additions to Haemonetics' equipment | ($51.9) | ($21.1) | ($28.2) | ($81.1) | ($51.8) |
| Proceeds from sale of property, plant and equipment | $1.4 | $23.3 | $1.8 | $1.6 | $2.0 |
| Free cash flow | $209.9 | $144.6 | $117.3 | $164.5 | $77.8 |


© 2026 Haemonetics Corporation

# Appendix C: Reconciliation of Cash Flows (continued)

| ($ millions) | Q2 YTD FY 2027 | Q2 YTD FY 2026 | Q2 YTD FY 2025 |
|---|---|---|---|
| Free Cash Flow Reconciliation | | | |
| Cash provided by operating activities | $180.4 | $128.7 | $21.4 |
| Capital expenditures | ($22.7) | ($8.8) | ($15.1) |
| Additions to Haemonetics' equipment | ($15.7) | ($29.1) | ($6.8) |
| Proceeds from sale of property, plant and equipment | $0.8 | $0.4 | $20.6 |
| Free cash flow | $142.9 | $91.2 | $20.1 |


© 2026 Haemonetics Corporation